EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery

Riddha Das iD, Elias A Halabi iD, Ina R Fredrich iD, Juhyun Oh iD, Hannah M Peterson iD, Xinying Ge iD, Ella Scott iD, Rainer H Kohler iD, Christopher S Garris iD, Ralph Weissleder iD

Advanced Science · 2023

DOI: 10.1002/advs.202303576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Riddha Das und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA, 02114, USA. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficient activation of professional antigen‐presenting cells—such as dendritic cells (DC)—in tumors and lymph nodes is critical for the design of next‐generation cancer vaccines and may be able to provide anti‐tumor effects by itself through immune stimulation. The challenge is to stimulate these cells without causing excessive toxicity. It is hypothesized that a multi‐pronged combinatorial approach to DC stimulation would allow dose reductions of innate immune receptor‐stimulating TLR3 agonists while enhancing drug efficacy. Here, a hybrid lipid nanoparticle (LNP) platform is developed and tested for double‐stranded RNA (polyinosinic:polycytidylic acid for TLR3 agonism) and immune modulator (L‐CANDI) delivery. This study shows that the ≈120 nm hybrid nanoparticles‐in‐nanoparticles effectively eradicate tumors by themselves and generate long‐lasting, durable anti‐tumor immunity in mouse models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsAnimalsMiceToll-Like Receptor 3Poly I-CDendritic Cells

Stichwörter der Autor:innen

TLRcancerdendritic cellsnanoparticlesvaccine stimulant

Substanzen

Toll-Like Receptor 3Poly I-CCancer Vaccines

Autor:innen und Institutionen

  • Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA, 02114, USA.
  • Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Department of Radiology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Department of Systems Biology, Harvard Medical School, 200 Longwood Ave, Boston, MA, 02115, USA.

ORCID-Profile: Riddha Das, Elias A Halabi, Ina R Fredrich, Juhyun Oh, Hannah M Peterson, Xinying Ge, Ella Scott, Rainer H Kohler, Christopher S Garris, Ralph Weissleder

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Boehringer Ingelheim

Zitieren

APA

Das, R., Halabi, E. A., Fredrich, I. R., Oh, J., Peterson, H. M., Ge, X., Scott, E., Kohler, R. H., Garris, C. S., & Weissleder, R. (2023). Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery. Advanced Science. https://doi.org/10.1002/advs.202303576

Vancouver

Das R, Halabi EA, Fredrich IR, Oh J, Peterson HM, Ge X, et al. Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery. Advanced Science. 2023. doi:10.1002/advs.202303576

BibTeX
@article{Das2023,
  author = {Das, Riddha and Halabi, Elias A and Fredrich, Ina R and Oh, Juhyun and Peterson, Hannah M and Ge, Xinying and Scott, Ella and Kohler, Rainer H and Garris, Christopher S and Weissleder, Ralph},
  title = {Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery},
  journal = {Advanced Science},
  year = {2023},
  doi = {10.1002/advs.202303576}
}
Kostenlos starten →